Oral News and Research

RSS

Wall Street Journal examines railway hospital in India

The Wall Street Journal examines Lifeline Express, "the world's first hospital on rails," which is run by Impact India, a group that "initially focused on immunization and prevention of diseases such as polio and malaria." Its success has spread to China and Zimbabwe, where three Lifeline Express trains are operated, and to "hospital river boats based on the India model have been set up to tend to patients in Bangladesh and Cambodia." It has also been used as a model for other health projects in India, according to the newspaper.

3 Apr 2010

Detroit cancer center to conduct free oral, head and neck cancer screenings

On Friday, April 16, from 2 - 5 p.m., the Barbara Ann Karmanos Cancer Center in Detroit will be conducting free oral, head and neck cancer screenings in conjunction with National Oral Head and Neck Cancer Awareness Week (April 12 – 18.) Some of the symptoms of oral cancer go unnoticed. A simple 10-minute screening exam can determine if there are problems and can help diagnose this disease in its early stage.

3 Apr 2010

Renhuang Pharmaceuticals' Siberian Ginseng capsule patent application passes preliminary SIPO review

Renhuang Pharmaceuticals, Inc., a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that on March 28, 2010, the Company's patent application for its proprietary Siberian Ginseng (Acanthopanax) Total Glucosides Total Flavonoids Soft Capsules and related formulation method passed a preliminary review conducted by the State Intellectual Property Office of the People's Republic of China ("SIPO").

2 Apr 2010

Teva Pharmaceutical Industries' Gemzar patent litigation: U.S. court issues decision

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the Southern District of Indiana issued a decision yesterday on two patents for Gemzar® (gemcitabine); the compound patent expiring on November 15, 2010, and a method of use patent expiring on May 7, 2013.

2 Apr 2010

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

Santarus, Inc., a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc., the consumer healthcare subsidiary of Merck & Co., Inc., has commenced promotion of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its licensing agreement with Santarus for the over-the-counter (OTC) market in North America. The OTC heartburn market in the U.S. is estimated at approximately $1.8 billion based on data from market research firm Information Resources, Inc. and Santarus estimates.

2 Apr 2010

Innovative drug design wins medical research prize

The development of a new way to treat iron overload disease has won the 2010 Sir Zelman Cowen Universities Fund Prize for Medical Research.

1 Apr 2010

New development in treatment of African Sleeping Sickness

African sleeping sickness or Human African Typanosomiasis is a potentially fatal disease affecting 50 to 70 thousand Africans each year. Carried by the bite tsetse fly this fatal disease is actually caused by a tiny parasite that attacks the nervous system, brain, spinal column resulting in mental confusion and finally death.

1 Apr 2010

BELLUS Health initiates Phase I clinical study for NRM8499

BELLUS Health Inc. announced today that, on March 30, 2010, the Company initiated a Phase I clinical study for NRM8499, a prodrug of tramiprosate. NRM8499 is intended for the treatment of Alzheimer's disease.

1 Apr 2010

Soligenix's revenues for 2009 increase by 22%

Soligenix, Inc., a late-stage biopharmaceutical company, today announced its financial results for 2009.

1 Apr 2010

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology taking place April 10 to 17, in Toronto, Canada.

1 Apr 2010

Major breakthrough may help develop low toxicity drugs for sleeping sickness

Scientists from the Drug Discovery Unit at the University of Dundee - working together with partners at the University of York and the Structural Genomics Consortium in Toronto - have made a major breakthrough in identifying new treatments for a fatal disease which infects tens of thousands of Africans each year.

1 Apr 2010

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

Hormone ghrelin may improve appetite in gastric cancer patients

In gastric cancer patients who have had part or all of their stomach removed, the hormone ghrelin may lessen post-operative weight loss and improve appetite, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.

1 Apr 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

31 Mar 2010

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta Incorporated today announced that the Company has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development.

31 Mar 2010

SANUWAVE Health reports net loss of $2.7M for three months ended December 31, 2009

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, reports its financial results for the fourth quarter and full year ended December 31, 2009, and on its progress for the year.

31 Mar 2010

In-depth practitioner training and experience critical for successful dental implant procedure

Burgeoning consumer demand for dental implants has prompted dentists nationwide to add implants to their practices, and some have mounted aggressive advertising campaigns to promote implants to consumers. But how can patients objectively evaluate the qualifications of a dentist to perform implant surgery?

31 Mar 2010

Plant-based system could help improve lives of hemophilic patients

Hemophilia, a disease linked with legends of European monarchs, frail heirs and one flamboyant charlatan called Rasputin, still afflicts many people today.

31 Mar 2010

Optometrists and dietitians are important part of health care team

For people with diabetes, proper nutrition can have a far-reaching effect on their health and wellness. They also have a higher risk of developing vision problems. March is National Nutrition Month and Save Your Vision Month, and the American Dietetic Association (ADA) and American Optometric Association (AOA) would like to remind people that optometrists and registered dietitians are an important part of the health care team.

31 Mar 2010

Renewed set of national policy guidelines to control diarrhoeal disease in Kenya

Today the Ministry of Public Health and Sanitation, together with the Department of Family Health (Division of Child and Adolescent Health), unveiled a renewed set of national policy guidelines to redouble diarrhoeal disease management and control efforts by putting proven interventions to work within the country's health system.

31 Mar 2010

Oral News and Research

Wall Street Journal examines railway hospital in India

Detroit cancer center to conduct free oral, head and neck cancer screenings

Renhuang Pharmaceuticals' Siberian Ginseng capsule patent application passes preliminary SIPO review

Teva Pharmaceutical Industries' Gemzar patent litigation: U.S. court issues decision

Schering-Plough HealthCare Products commences promotion of ZEGERID OTC in North America

Innovative drug design wins medical research prize

New development in treatment of African Sleeping Sickness

BELLUS Health initiates Phase I clinical study for NRM8499

Soligenix's revenues for 2009 increase by 22%

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

Major breakthrough may help develop low toxicity drugs for sleeping sickness

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Hormone ghrelin may improve appetite in gastric cancer patients

RXi Pharmaceuticals reports net loss of 28% for 2009

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

SANUWAVE Health reports net loss of $2.7M for three months ended December 31, 2009

In-depth practitioner training and experience critical for successful dental implant procedure

Plant-based system could help improve lives of hemophilic patients

Optometrists and dietitians are important part of health care team

Renewed set of national policy guidelines to control diarrhoeal disease in Kenya

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News